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Abstract
In an effort to better utilize published evidence obtained from animal experiments, system-
atic reviews of preclinical studies are increasingly more common—along with the methods
and tools to appraise them (e.g., SYstematic Review Center for Laboratory animal Experi-
mentation [SYRCLE’s] risk of bias tool). We performed a cross-sectional study of a sample
of recent preclinical systematic reviews (2015–2018) and examined a range of epidemiolog-
ical characteristics and used a 46-item checklist to assess reporting details. We identified
442 reviews published across 43 countries in 23 different disease domains that used 26 ani-
mal species. Reporting of key details to ensure transparency and reproducibility was incon-
sistent across reviews and within article sections. Items were most completely reported in
the title, introduction, and results sections of the reviews, while least reported in the methods
and discussion sections. Less than half of reviews reported that a risk of bias assessment
for internal and external validity was undertaken, and none reported methods for evaluating
construct validity. Our results demonstrate that a considerable number of preclinical system-
atic reviews investigating diverse topics have been conducted; however, their quality of
reporting is inconsistent. Our study provides the justification and evidence to inform the
development of guidelines for conducting and reporting preclinical systematic reviews.
Introduction
Systematic reviews and meta-analyses are essential tools for synthesizing evidence in a trans-
parent and reproducible manner [1]. They provide a rigorous method to comprehensively
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identify, summarize, evaluate, and appraise the available evidence on a topic. Clinical system-
atic reviews have been used for over 3 decades by policy makers, clinicians, and other stake-
holders to inform decision-making and evidence-based practice [2]. More recently, systematic
reviews of preclinical research have been used to identify, summarize, evaluate, and appraise
laboratory-based studies [3–5]. With an emerging recognition of the importance of rigor and
reproducibility, preclinical systematic reviews have been recognized to provide important
information to inform the translational pathway of novel therapeutics [6].
The popularity of preclinical systematic reviews has been growing over the past decade.
Groups such as the Collaborative Approach to Meta-Analysis and Review of Animal Data
from Experimental Studies (CAMARADES, http://www.dcn.ed.ac.uk/camarades/) and SYs-
tematic Review Center for Laboratory animal Experimentation (SYRCLE, https://www.syrcle.
nl/) have been established in part to provide support for researchers conducting systematic
reviews and meta-analyses of experimental animal studies. Although the Preferred Reporting
Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines have been critical to the
proper reporting of systematic reviews [7,8], they lack specificity for reporting systematic
reviews of preclinical research. There are fundamental differences between preclinical and
clinical systematic reviews of interventions. For instance, subjects are laboratory animals
instead of humans, and studies employ different procedures compared with clinical studies
(e.g., inducing the disease in animals to mimic the human condition, humanely killing animals
to evaluate outcomes, etc.). Therefore, species- and strain-specific effects, along with unique
elements of data abstraction, may need to be considered. In addition, preclinical systematic
reviews are sometimes performed as precursors to attempted clinical translation of a novel
therapy. Therefore, in addition to risk of bias, exploring construct validity of included primary
studies (i.e., how well the animal models mimic the disease of interest) may provide important
insights on the potential for translation [9]. Finally, it is commonplace to include primary
studies with multiple experiments, each with many experimental arms; this requires both sig-
nificant efforts to identify specific data to include, as well as special considerations for how
data will be handled when analyzed. As this field continues to develop, it is important to audit
practices and ensure that norms of systematic review conduct and reporting are adhered to.
Several reports have been performed to identify and characterize published systematic reviews
of preclinical experiments. The most recent evaluation published by Mueller and colleagues
[5] summarized 512 preclinical systematic reviews published between 1989 and 2013. They
found the quality of reporting in these reviews low, the majority not reporting assessing the
risk of bias or heterogeneity of included studies.
The prevalence and state of reporting of preclinical systematic reviews has not been for-
mally evaluated since 2014 (by Mueller and colleagues) [5]. It is unknown if the reporting of
these reviews has improved. Thus, a contemporary assessment of published preclinical system-
atic reviews is warranted. This assessment will help inform the future development of report-
ing guidelines designed specifically for preclinical systematic reviews, as an extension to the
PRISMA statement.
Methods
The protocol for this study was posted on Open Science Framework (https://osf.io/9mzsv/)
and is part of a larger program of research to generate an extension for the PRISMA guidelines
specific to preclinical in vivo animal experiments (https://osf.io/kv3ed/). It is important to note
that the reporting assessment described here is not an extension to PRISMA; instead, the
results of this study will be used to inform the development of the aforementioned preclinical
extension (Delphi protocol: https://osf.io/4wy3s/).
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Eligibility criteria
All preclinical systematic reviews that investigated interventions using in vivo animal research
were eligible. Systematic reviews with or without meta-analyses were included. We only con-
sidered in vivo animal research, as we intend to use the findings of this work to inform guide-
lines that are specifically for reporting preclinical systematic reviews of in vivo experiments.
We included systematic reviews that met at least 3 of the 4 following statements according
to the 2009 PRISMA statement [9]: (a) a clearly stated set of objectives with explicit methodol-
ogy; (b) a systematic search was employed; (c) an assessment of validity of findings (e.g., risk of
bias assessment) was conducted; and (d) systematic presentation, synthesis of characteristics
and findings of the included studies.
We defined preclinical as research investigating medically relevant interventions that is
conducted using nonhuman models, with an intention to progressing to testing efficacy in
human participants prior to being approved. Models were limited to in vivo (in living ani-
mals) experiments; thus, reviews of solely in vitro (in cells, microorganisms, or biological
molecules) or ex vivo (in tissue removed from a living subject) experiments were excluded.
We did not limit inclusion by the domain of the preclinical study or potential clinical scope.
We included any potentially therapeutic intervention including, but not limited to sub-
stances, antibodies, vaccines, gene therapies, technical devices and other non-pharmaco-
logic interventions (e.g., surgical procedures or dietary interventions), combination
therapies, or novel enhancements of already established clinical therapies. We did not limit
inclusion based on comparator groups or outcomes measured. We excluded clinical system-
atic reviews, meta-analyses of datasets (e.g., large databases) not gathered from literature or
retrieved from non-laboratory studies, as well as non-English articles, scoping reviews, nar-
rative reviews, rapid reviews, and systematic reviews published only as conference
abstracts/proceedings.
Information sources and search strategy
A comprehensive literature search was developed and conducted in conjunction with an infor-
mation specialist. We searched MEDLINE via Ovid, Embase via Ovid, and Toxline for preclin-
ical systematic reviews of in vivo animal research (2015 to 2018 inclusive; searches performed
on January 13, 2017 and updated January 24, 2018 and March 21, 2019). The details of the
search strategy are available in S1 Appendix.
Screening and data extraction
The literature search results were uploaded to Distiller Systematic Review Software (Distil-
lerSR, Evidence Partners, Ottawa, Canada). DistillerSR is cloud-based software that manages
references and provides customized reports for accurate review. Titles, abstracts, and full text
were screened for inclusion by 2 independent reviewers using the eligibility criteria outlined
above. Disagreements were resolved through consensus or by a third party, if necessary.
Where titles and abstracts appeared to meet the inclusion criteria or where there was uncer-
tainty, we reviewed the full text. Prior to the formal full-text screening, a calibration test of 13
systematic reviews was performed to refine the screening form to ensure no misinterpretation
of the eligibility criteria. Inter-rater agreement was assessed (Cohen’s kappa coefficient). The
reasons for article exclusion at the full-text level were recorded. The study selection process
was documented using the 2009 PRISMA flow diagram.
After identifying all eligible preclinical systematic reviews, we extracted data in duplicate
with conflicts resolved by consensus or a third party. Prior to the formal data extraction, a
pilot test on 13 reviews was performed to refine the data form and to ensure a high level of
PLOS BIOLOGY Reporting of preclinical systematic reviews
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inter-rate agreement. The extracted study characteristics included details about the publication
(corresponding author’s name, their contact information, the country their institution was
located in, and publication year), the animal species investigated, and the disease domain
being investigated (e.g., cardiovascular disease). We extracted the number of in vivo publica-
tions included in each review, the sources of funding, the category (pharmacological or non-
pharmacological), and specific name of interventions.
Assessment of reporting
We next evaluated the quality of reporting in a random sample of 25% included systematic
reviews. This sample size was chosen based on available resources. These were selected using
the embedded randomize function in DistillerSR. Our aim was to assess the reporting in pre-
clinical systematic reviews; thus, we only selected studies in which the majority of data were
derived from preclinical in vivo studies. Two reviewers determined eligibility of the randomly
selected studies—resampling ineligible reviews until the full sample of 25% was reached. Two
reviewers then independently assessed the reporting in the sample of preclinical systematic
reviews using a reporting checklist developed a priori (described below). The reporting assess-
ment was piloted on 7 reviews from the sample to ensure that reviewers were evaluating the
reporting items consistently. Any disagreements were resolved by discussion or by a third
party when necessary.
Generating checklist
To create the checklist for the reporting assessment, we consulted PRISMA 2009 [9], along
with 4 sets of expert guidance in preclinical systematic review [3,10–12]. All items from each
source were included in an omnibus draft checklist, where each item was framed as 1 or more
“binary” items (that could be answered with a clear yes or no rather than having multiple ques-
tions or conditions). This list was compared against additional sources, PRISMA 2020 (pre-
print) [13] and several previously published assessments of reports of preclinical systematic
reviews [4,5,14], to generate a list of items. Items from the list that appeared only relevant to
clinical systematic reviews were further evaluated by our team. If these items could not be
modified for the preclinical context, they were removed. After discussion and feedback from
experts in the fields of systematic review reporting and preclinical research, a final checklist
containing 46 items (51 with included subitems) was generated. This was a collaborative and
iterative process including all coauthors over the course of several virtual meetings. It is impor-
tant to note that this checklist is not intended to be an extension for PRISMA, but rather a list
of key reporting items our team wanted to assess.
Items were arranged by the following manuscript sections: title, introduction, methods,
results, discussion, and other. We did not evaluate items that are specific to review abstracts, as
the guideline for abstracts vary substantially by journal. Items were assessed in each review as
being reported (“yes”) or not (“no”), or not applicable to the review (“NA”). If a review did not
contain quantitative data (i.e., no meta-analysis), “NA” was selected for all items relating to
quantitative data/analysis (e.g., report methods for extracting numerical data from report).
One exception was an assessment of the review’s main objective/question (which would ideally
be presented in a population, intervention, comparison, outcome [PICO] format). This could
be scored as a “yes,” “no,” or “partial,” where “partial” represented some, but not all, relevant
PICO items of the question being stated. This checklist was piloted and refined by 2 indepen-
dent reviewers to improve its utility in practical application before using it to assess systematic
review reporting. The checklist can be found in S1 Checklist.
PLOS BIOLOGY Reporting of preclinical systematic reviews
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Data analysis
The collected data are presented using descriptive statistics (total counts, medians, and ranges),
as well as narratively when appropriate.
Results
Search results
Our searches identified a total of 2,356 records (2015 to 2018, inclusive, Fig 1). We excluded
1,585 records on the basis of abstract screening. Of 771 full-text articles retrieved for further
evaluation, 329 were excluded (40% being commentaries, editorials, or short review/reports).
Of note, 73 articles included in the abstract level for having “systematic review” in the title
were later excluded at the full-text stage as they were not systematic reviews. The agreement
between reviewers across the screening stage was very high (kappa = 0.93). A total of 442 pre-
clinical systematic reviews met our inclusion criteria.
Descriptive characteristics of included systematic reviews
Twenty-seven percent of reviews were published in 2015, 15% in 2016, 20% in 2017, and 38%
were published in 2018. Corresponding authors resided in 43 different countries (Fig 2, S1
Table). Three hundred and thirty-four reported on funding, with 248 having receiving funding
from 1 or more sources; 86 reviews stated they had no funding (Table 1).
Fig 1. PRISMA flow diagram of study selection process. PRISMA, Preferred Reporting Items for Systematic reviews
and Meta-Analyses.
https://doi.org/10.1371/journal.pbio.3001177.g001
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Fig 2. Heatmap of the number of preclinical systematic reviews published by country. No systematic reviews were published in the counties with
gray coloring. The map was created using Tableau software.
https://doi.org/10.1371/journal.pbio.3001177.g002
Table 1. Descriptive characteristics of included preclinical systematic reviews.
Category Characteristic Number (%), n = 442




Source of funding Government 163 (37)
Academia 78 (18)
Foundation/charity 73 (17)
Pharmaceutical company 13 (3)
Hospital 10 (2)
Unfunded 86 (20)
Not reported 108 (24)








Not reported 5 (1)
�Percent calculation out of the number of funded reviews that reported the source (n = 248).
https://doi.org/10.1371/journal.pbio.3001177.t001
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The median number of primary publications included in the preclinical systematic reviews
was 24 (range: 1 to 1,342). Eighty-two (19%) reviews contained data from both human studies
(clinical trials and case studies) and in vivo animal experiments, and 97 (22%) reviews contained
data from both in vitro and in vivo preclinical experiments. There were 26 animal species used
in the included primary studies within the 442 preclinical systematic reviews (Fig 3, S2 Table).
Twenty-three reviews did not report the species of animals used in their included primary stud-
ies. The median number of included species within the reviews was 2 (range: 1 to 9).
The preclinical systematic reviews investigated 23 different disease domains (Table 2). The
most common were musculoskeletal system and connective tissue disorders (74 reviews; 17%),
followed by disorders and afflictions to the nervous system (70 reviews; 16%). For the majority
of reviews (363 reviews; 82%) the focus was on one disease domain, while 79 (18%) covered
multiple disease domains.
Two-hundred and thirty-nine (54%) reviews reported pharmacological interventions, and
203 (46%) reported non-pharmacological interventions. Pharmacological interventions
included substances like synthetic drugs, vaccines, and organic molecules. Within the 203
reviews that had a non-pharmacological intervention, 46 (10%) were cell therapies, 44 (10%)
were surgery or invasive procedures, and 21 (5%) were medical physics interventions (e.g.,
ultrasound therapies) (Table 3).
Reporting characteristics from a sample of systematic reviews
To assess the completeness of reporting within preclinical systematic reviews, we selected a
random sample of 110 articles (25% of the 442 identified reviews): 64 of which evaluated
Fig 3. Infographic of animal species/class/family included in the preclinical systematic reviews. The structure of the pyramid and positioning of each species/class/
family reflects their frequency and does not reflect hierarchy. [Values represent frequency and (%).]. The figure was created using non-copyrighted biological silhouettes
retrieved from Phylopic.org.
https://doi.org/10.1371/journal.pbio.3001177.g003
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Table 2. Disease domains investigated in the preclinical systematic reviews.
Category Characteristic Number (%), of
n = 442
Type of disease domain Musculoskeletal system and connective tissue 74 (17)
Nervous system 70 (16)
Cardiovascular system 66 (15)
Endocrine, nutritional, and metabolic diseases 42 (10)
Cancer 38 (9)
Toxicology 38 (9)
Mental and behavior 37 (8)
Genitourinary system 24 (5)
Skin and subcutaneous tissue 20 (5)
Digestive system 20 (5)
Critical illness 18 (4)
Infectious and parasitic diseases 17 (4)
Respiratory system 13 (3)
Pain and analgesia 13 (3)
General and whole-body health 10 (3)
Conditions originating in the perinatal period 9 (2)
Pharmacokinetic, biological activity, and dose–
response
5 (1)
Blood and immune disorders 6 (1)
Eye 6 (1)
Mouth 6 (1)
Congenital malformations 5 (1)
Surgery and imaging techniques 4 (0.9)
Auditory system 1 (0.2)







Table 3. Intervention and intervention subgroups evaluated in the preclinical systematic reviews.
Intervention Number (%), of n = 442 Subgroup Number (%), of n = 442
Pharmacological 239 (54) NA
Non-pharmacological 203 (46) Cell therapy 46 (10)
Surgery or invasive procedures 44 (10)
Medical physics 21 (5)
Dietary interventions 13 (3)
Blood transfusions or modifications 11 (3)
Animal model validation 10 (2)
Tactile stimulus interventions 10 (2)
Exercise and physical activity 10 (2)
Oxygen therapy 7 (2)
Gene therapy 7 (2)
Other 24 (5)
https://doi.org/10.1371/journal.pbio.3001177.t003
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pharmacological interventions and 46 evaluated non-pharmacological interventions (Fig 4).
Inter-rater agreement between reviewers using our 46-item checklist (51 with subitems) was
high (kappa = 0.89). The reporting assessments for the sample of 110 preclinical reviews is
located in S3 Table.
Reporting of title and introduction
Many (92; 84%) of the reviews indicated that the report was a “systematic review” in the title,
while approximately half (54; 49%) reported that the review contained animal experiments in
the title. Forty-five (41%) reviews reported both of these elements in the title. Within the intro-
duction, most reviews described the human disease or health condition being modeled (104;
95%) and described the biological rationale for testing the intervention (106; 96%). Eighty
(73%) reviews explicitly stated the review question(s) addressed (Fig 5).
Reporting of methods
Twenty-two reviews (20%) reported a protocol had been developed a priori, of which 18 indi-
cated where it could be accessed. Two of these reviews reported whether or not there were
Fig 4. Flowchart of reviews selected for the reporting assessment.
https://doi.org/10.1371/journal.pbio.3001177.g004
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deviations in protocol. Of the reporting items dedicated to study inclusion criteria, the descrip-
tion of the eligible interventions/exposures was the highest reported item (93%). This was fol-
lowed by reporting the animal species (65%), reporting outcomes (63%), and reporting the
type/details of the animal models (53%) that could be included in the review. Thirty-five per-
cent of reviews reported the eligible intervention timing (prevention versus rescue), although
this item was not applicable to 31% of the reviews, as intervention timing was not a consider-
ation. Sixty-nine percent reported the article inclusion limits (year of publication, type of arti-
cle, and language restrictions).
In the methods section, 76% of reviews reported a full or a representative search strategy,
and 72% described the study screening/selection process—of which 18 reviews (10%) reported
the platform used to screen. Roughly two-thirds (62%) of reviews stated the number of inde-
pendent screeners, while less than half (44%) reported the number of reviewers extracting
data. Half of the reviews (49%) reported the methods and tool to measure study quality/risk of
bias, while no (0%) reviews described methods for assessing construct validity (i.e., potential
relevance to human health) [15]. For those in which it was applicable, 23% reported the meth-
ods for a publication bias assessment (Fig 6).
Reporting of results
In the results section, almost all (106; 96%) the sampled reviews reported the number of
included studies/publications, and 44% reported the number of independent experiments
included in the analysis. The majority of reviews (86%) included a study selection flow dia-
gram of the study selection process, and details such as study characteristics, animal species,
and animal models, were generally well reported. For quality assessment measures, less than
half (46%) reported the results of a risk of bias assessment, and 25% reported the results of
assessing publication bias or that this assessment was not possible/done (Fig 7).
Reporting of discussion
Within the discussion section, a minority of reviews (31%) discussed the impact of the risk of
bias of the primary studies. Sixty-five percent of reviews discussed the limitations of the pri-
mary studies and outcomes to be drawn, while 56% of reviews discussed the limitations of the
review itself. Twenty-one (19%) reviews reported on data sharing (Fig 8).
Fig 5. Level of reporting (count and percent) for the items within the title and introduction sections. PICO, population, intervention,
comparison, outcome.
https://doi.org/10.1371/journal.pbio.3001177.g005
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Fig 6. Level of reporting (count and percent) for the items within the methods section. CAMARADES, Collaborative Approach to Meta-
Analysis and Review of Animal Data from Experimental Studies; DistillerSR, Distiller Systematic Review Software; SYRCLE, SYstematic Review
Center for Laboratory animal Experimentation.
https://doi.org/10.1371/journal.pbio.3001177.g006
Fig 7. Level of reporting (count and percent) for the items within the results section. PRISMA, Preferred Reporting Items for Systematic reviews
and Meta-Analyses.
https://doi.org/10.1371/journal.pbio.3001177.g007
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Method and results—For reviews with quantitative analysis
Of the 110 reviews, 44 (40%) performed a quantitative analysis. The 44 quantitative reviews
investigated 17 of the 23 diseases domains: cardiovascular system disorders (9 reviews; 20%),
followed by musculoskeletal and connective tissue disorders, and nervous system disorders (7;
16% each). Twenty-five (60%) quantitative reviews investigated pharmacological interven-
tions, and 19 (40%) investigated non-pharmacological interventions. Characteristics of the 44
quantitative reviews are found in S4 and S5 Tables.
The following reporting items were specific for the quantitative reviews and were not appli-
cable to reviews that did not perform a quantitative analysis. For the reviews that did not per-
form a quantitative analysis, the quantitative items were evaluated as “NA” (as described in the
methods). Twenty-two (50% of 44) quantitative reviews described methods for extracting
numerical data from primary studies (e.g., how data were extracted from graphical format,
which is common in preclinical experimental studies). The majority (40; 95%) of quantitative
reviews reported the methods for synthesizing the effect measure and methods for assessing
statistical heterogeneity between studies. Fourteen reviews (32% of 44) reported methods for
any data transformation needed to make extracted data suitable for analysis. Sixteen reviews
(36% of 44) reported methods for handling shared control groups, and 13 (30% of 44)
described methods for handling effect sizes over multiple time points, 2 common features in
preclinical experimental studies. Of the 35 reviews that reported a subgroup or sensitivity anal-
ysis in the results, 33 reported the methods for these analyses. Within the results section, the
confidence intervals of outcomes and a measure of heterogeneity were reported by 88% and
84% of quantitative reviews, respectively, while 29% of reviews in the sample reported the
results of a subgroup or sensitivity analysis (Fig 9).
Of the 110 reviews, 46 (42%) explicitly mentioned following/using a reporting guideline or
provided a completed reporting checklist. Forty-five of which reported using the PRISMA
2009 statement, and one used the Meta-analyses Of Observational Studies in Epidemiology
(MOOSE) checklist.
Discussion
This review provides a comprehensive characterization of preclinical systematic reviews and
an evaluation of their reporting. Our results suggest that systematic review methodology is
being applied to a diverse range of preclinical topics, and their production is increasing. Com-
pared to the last assessment of preclinical systematic reviews published in 2014, the number of
preclinical systematic reviews has nearly doubled in just 4 years. We identified that the
Fig 8. Level of reporting (count and percent) for the items within the discussion and other sections.
https://doi.org/10.1371/journal.pbio.3001177.g008
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reporting of methodology and results are not optimal. Without complete and transparent
reporting of methods, it is likely not possible to gauge the trustworthiness of the results, a
major limitation of any research project.
Established guidelines exist for both reporting in vivo preclinical experiments and clinical
systematic reviews, although guidelines for reporting systematic reviews of animal experiments
have yet to be developed. Similar to a landmark evaluation of clinical systematic reviews prior
to the development of the 2009 PRISMA guidelines [16] and for the PRISMA 2020 update
[17], we created a checklist of reporting items to assess, and we chose a sample of articles that
could be feasibly evaluated. Many of the included reviews reported that they followed system-
atic review reporting guidelines (e.g., the PRISMA statement); however, most did not report
on all required items. Fundamental items rarely reported included providing a search strategy,
reporting a review protocol, describing methods for assessing the risk of bias, reporting the
limitations of the review, and data sharing. Our findings are similar to an evaluation of 300
clinical systematic reviews indexed in February 2014, which found that at least a third of the
reviews did not report use of a review protocol, years of coverage of the search, methods for
data extraction, and methods for study risk of bias assessment [18].
Encouragingly, some of the reporting items assessed in previous reporting assessments
have improved in our evaluation. Mueller and colleagues [5] found that 62% of the reviews
they identified provided a flow diagram of included studies; we found that 86% did so (Z-test,
p< 0.0001). Similarly, reporting of funding also improved (78% versus 38%; Z-test,
p< 0.00001). Fourteen percent of reviews assessed publication bias in the previous reporting
assessment, while 25% of reviews reported the results of publication bias in our updated evalu-
ation (Z-test, p = 0.01). We speculate that the improved reporting of some items may be
Fig 9. Level of reporting (count and percent) for the quantitative items within the methods and results sections.
https://doi.org/10.1371/journal.pbio.3001177.g009
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explained in part by the increased funding provided to more recent reviews as well as estab-
lished leadership by groups such as CAMARADES and SYRCLE. Since its establishment in
2004, CAMARADES has published several resources to guide investigators in the conduct and
reporting of preclinical systematic reviews [3,12,19]. Additional to these resources, SYRCLE
disseminated tools specifically for writing a protocol for a preclinical systematic review [20],
searching for animal studies [21–23], and assessing risk of bias of preclinical studies in 2014
[24]. Also, the international registry for systematic review protocols (PROSPERO, https://
www.crd.york.ac.uk/PROSPERO/) began accepting protocols for systematic reviews of animal
studies relevant to human health in October 2017, which may have further improved their
planning and conduct.
The improvements we see in our review provide evidence that these initiatives may have
contributed to better reporting quality in preclinical systematic reviews; however, significant
deficits still exist with half of studies failing to assess risk of bias. In addition, items that are
unique to preclinical systematic reviews (e.g., construct validity [15]) were not evaluated objec-
tively. Although authors may speculate on translational potential in the discussion section of
papers, it remains rare for reproducible frameworks to be used to evaluate it. In part, this may
reflect a lack of consensus on the definition of “construct validity”; although the concept of
translation is often discussed, variable terms and approaches have been suggested (e.g., transla-
tion as a component of external validity [25], using a unique term such as “translational valid-
ity” [26], etc.). Defining this concept further through future research may be warranted.
Overall, identified issues with reporting suggest that further guidance, such as a PRISMA
extension specific for preclinical systematic reviews, may further improve reporting practices.
Indeed, previous research has demonstrated that journals endorsing the PRISMA guidelines
publish systematic reviews that are more completely reported and of higher quality [27,28].
These guidelines will need to be supported by further education and incentives in order to
ensure good uptake and appropriate application, such as journals requiring the use and inclu-
sion of the reporting checklist within their published articles.
In addition to the development of reporting guidelines, other initiatives must be considered
to improve the state of reporting and quality of preclinical systematics reviews. Journals, fund-
ers, and reviewers could contribute to this improvement by advocating and appealing for data
sharing, registration of protocols a priori, and recommending the use of tools and resources
created by SYRCLE, CAMARADES, and similar groups. Moreover, reporting transparency
could be improved by moving beyond simple endorsement and instead enforcing the use of a
reporting checklist.
Strengths and limitations
A strength of this study is our use of a sensitive search strategy to identify systematic reviews of
in vivo animal experiments. However, the scope of our review may be seen as a limitation as
our search focused upon in vivo research of largely therapeutic interventions. It should be
acknowledged that in vitro and ex vivo are important areas of preclinical research, and thus the
results from this study may not be representative of all preclinical systematic reviews. Further-
more, our sample was restricted to systematic reviews published in the English language,
which may have caused the omission of relevant data and the introduction of bias.
A potential limitation is the timeframe of our sample, as we included reviews from 2015 to
2018 inclusively. Although we chose this sample to capture the state of reporting in preclinical
systematic reviews after the previous assessment in 2014, we acknowledge that the state of
reporting may have changed from 2018; however, it is important to note that no major initia-
tives to address systematic review reporting have occurred since that time.
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Additionally, to assess the state of reporting, we selected a sample of 25% of the identified
reviews. Moreover, we applied eligibility criteria for inclusion in the reporting assessment with
the aim of ensuring the reviews were predominantly preclinical in vivo animal reviews, rather
than clinical reviews with a small amount of animal data included. Both of these may create
bias, as the sample may not be completely representative of the full population of reviews.
In addition, some of the items in our reporting assessment may not be generalizable to other
forms of preclinical systematic reviews (e.g., those not focused on therapeutic interventions).
Future directions
Our results show that the number of preclinical systematic reviews continues to increase com-
pared to a previous review published in 2014. Although reporting quality has demonstrated
some potential improvements, there still remains room for significant improvement. This ech-
oes the past state of reporting within clinical systematic reviews, where historic poor reporting
hampered their quality and potentially limited their utility. To address the insufficient report-
ing and improve transparency in clinical reviews, the PRISMA statement was developed.
Although observational studies have suggested that the adoption of PRISMA has led to
improved reporting of systematic reviews, it does not completely facilitate reporting within
reviews of preclinical animal experiments. This is likely due to the unique differences between
clinical and animal research. Specifically, our results provide rationale for a preclinical animal
experiments extension of PRISMA and highlight areas of most deficient reporting. This will
inform the development of a PRISMA preclinical systematic review extension.
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